Skip to main
FDMT

FDMT Stock Forecast & Price Target

FDMT Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

4D Molecular Therapeutics is making significant progress in their Phase III clinical trials for 4D-150, which has a $8.82 NPV/share valuation and high potential to penetrate the wet AMD and DME markets with initial pricing at $70,000 per eye. The biggest risk to their success lies in their manufacturing capabilities, as AAV-based GT products are novel and could face delays or constraints if sufficient capacity is not developed.

Bears say

4D Molecular Therapeutics is currently ramping sales, but may face challenges in achieving profitability due to the need for additional financing and potential competition from other therapies. While their technology for targeted gene therapy delivery is promising, the clinical data for their lead therapy 4D-710 in cystic fibrosis show variable efficacy and further studies are needed to confirm its clinical benefit. Additionally, regulatory and manufacturing hurdles may also impact the success of their pipeline products.

FDMT has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of 4D Molecular Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About 4D Molecular Therapeutics (FDMT) Forecast

Analysts have given FDMT a Strong Buy based on their latest research and market trends.

According to 6 analysts, FDMT has a Strong Buy consensus rating as of May 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

4D Molecular Therapeutics (FDMT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.